Nicox SA

ALCOX

FR0013018124

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:00 2024-05-31 EDT			5-day change	1st Jan Change
0.3375 ^EUR	0.00%		-9.40%	-23.64%

05-30	Nicox : launch of a capital increase	CF
04-22	Nicox: cash position of 9.1 million euros at the end of March	CF

Nicox S.A. Announces Retirement of José Boyer as Interim Head of R&D

September 27, 2021 at 01:30 am

Nicox S.A. announced that Dr. José Boyer has retired as Interim Head of R&D, although he will continue to advise the Company as a consultant.

Latest news about Nicox SA

Nicox : launch of a capital increase	05-30	CF
Nicox: cash position of 9.1 million euros at the end of March	04-22	CF
Nicox, BlackRock Sign Deal for Debt Restructuring	02-28	MT
Nicox Names Chief Business Officer as New CEO	02-28	MT
Nicox SA Announces CEO Changes	02-28	CI
Nicox, Kowa Team Up to Develop, Commercialize NCX 470 Eyedrop in Japan	02-08	MT
Nicox to Receive US Patent Extension for Latanoprostene Bunod	01-31	MT
Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA	01-31	CI
Nicox: sales up 29% in 2023	01-25	CF
Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan	12-14	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-20	CI
Nicox: surrounded after market study	23-07-10	CF
Nicox's New Drug Application for Eye Drop Medicine Gets Priority Review Status in China	23-04-28	MT
Nicox Set for Euronext Growth Paris Transfer	23-04-26	MT
Nicox: new data on two compounds	23-04-26	CF
Nicox: Armistice Capital falls below 5% threshold	23-04-25	CF
Global markets live: ASML, Netflix, United Airlines, Morgan Stanley, Tesla...	23-04-19
Nicox: cash position shrinks, share price plummets	23-04-19	CF
Nicox Jumps 28% as Chinese Partner Files New Drug Application for Eye Drop	23-04-14	MT
Nicox: share price soars, progress on Zerviate in China	23-04-14	CF
Nicox SA Announces New Drug Application Submission for ZERVIATE in China	23-04-14	CI
Global markets live: UBS, Berkshire Hathaway, First Republic Bank, Goldman Sachs...	23-03-20
Nicox: reduced losses in 2022, but reduced cash flow	23-03-20	CF
Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-19	CI
Nicox: HBM Healthcare Investments falls below 5% threshold	23-01-23	CF

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Sector

Pharmaceuticals

Calendar

2024-06-28 - Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Nicox SA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3375 EUR

Average target price

1 EUR

Spread / Average Target

+196.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
NICOX SA	-23.64%	18.3M
MERCK KGAA	+15.54%	77.63B
KYOWA KIRIN CO. LTD.	+12.05%	8.78B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+58.17%	4.93B
SK BIOPHARMACEUTICALS CO., LTD.	-14.94%	4.79B
YUHAN CORPORATION	0.00%	3.8B
INDIVIOR PLC	+21.94%	2.46B
BETTA PHARMACEUTICALS CO., LTD.	-26.63%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.75%	2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-37.97%	1.96B

Specialty & Advanced Pharmaceuticals

Nicox SA

Equities

ALCOX

FR0013018124

Pharmaceuticals

Nicox S.A. Announces Retirement of José Boyer as Interim Head of R&D

Latest news about Nicox SA

Chart Nicox SA

Company Profile

Income Statement Evolution

Ratings for Nicox SA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals